Koers XSPY PHAR Nasdaq Stockholm
Aandelen
SE0009973563
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 713 mln. 67,33 mln. 0 62,84 mln. | Omzet 2025 * | 789 mln. 74,46 mln. 0 69,5 mln. | Marktkapitalisatie | 2,71 mld. 256 mln. 0 239 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 596 mln. 56,25 mln. - 52,5 mln. | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 3,44 x |
Nettoliquiditeiten 2024 * | 262 mln. 24,71 mln. 0 23,06 mln. | Nettoliquiditeiten 2025 * | - 0 - 0 | EV/omzet 2025 * | 3,44 x |
K/w-verhouding 2024 * |
3,75
x | K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
1,24% | Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 59,23% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Per Andersson
CEO | Chief Executive Officer | 57 | 01-09-06 |
Director of Finance/CFO | 52 | 08/02 | |
Thomas Walz
CTO | Chief Tech/Sci/R&D Officer | - | 01-09-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 71 | 01-01-15 | |
Carl-Johan Spak
BRD | Director/Board Member | 68 | 01-01-15 |
Chairman | 70 | 19-05-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,20% | 121 mld. | |
+19,67% | 113 mld. | |
+18,95% | 26,02 mld. | |
-23,86% | 19,39 mld. | |
-19,03% | 15,91 mld. | |
-20,90% | 15,09 mld. | |
-46,14% | 15,06 mld. | |
+63,85% | 14,93 mld. | |
+4,49% | 13,85 mld. |